ATE508202T1 - Verfahren zur diagnose von brustkrebs - Google Patents

Verfahren zur diagnose von brustkrebs

Info

Publication number
ATE508202T1
ATE508202T1 AT04773526T AT04773526T ATE508202T1 AT E508202 T1 ATE508202 T1 AT E508202T1 AT 04773526 T AT04773526 T AT 04773526T AT 04773526 T AT04773526 T AT 04773526T AT E508202 T1 ATE508202 T1 AT E508202T1
Authority
AT
Austria
Prior art keywords
breast cancer
brc
cells
methods
discriminates
Prior art date
Application number
AT04773526T
Other languages
German (de)
English (en)
Inventor
Yusuke Nakamura
Toyomasa Katagiri
Shuichi Nakatsuru
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Application granted granted Critical
Publication of ATE508202T1 publication Critical patent/ATE508202T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT04773526T 2003-09-24 2004-09-24 Verfahren zur diagnose von brustkrebs ATE508202T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50557103P 2003-09-24 2003-09-24
PCT/JP2004/014438 WO2005028676A2 (en) 2003-09-24 2004-09-24 Method of diagnosing breast cancer

Publications (1)

Publication Number Publication Date
ATE508202T1 true ATE508202T1 (de) 2011-05-15

Family

ID=34375580

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04773526T ATE508202T1 (de) 2003-09-24 2004-09-24 Verfahren zur diagnose von brustkrebs

Country Status (9)

Country Link
US (3) US7531300B2 (2)
EP (2) EP1668354A2 (2)
JP (3) JP4579246B2 (2)
CN (2) CN1898563B (2)
AT (1) ATE508202T1 (2)
DE (1) DE602004032556D1 (2)
ES (1) ES2365732T3 (2)
TW (2) TW200512298A (2)
WO (2) WO2005029067A2 (2)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1699937A2 (en) * 2003-12-05 2006-09-13 Erasmus MC Predicting response and outcome of metastatic breast cancer anti-estrogen therapy
FR2875512B1 (fr) * 2004-09-17 2011-02-04 Diagnogene S A Biopuce de diagnostic du caractere metastatique ou localise d'une tumeur mammaire, procede et kit d'utilisation
CA2599875A1 (en) * 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited Preventive/therapeutic agent for cancer
ATE473761T1 (de) * 2005-03-11 2010-07-15 Oncotherapy Science Inc Verfahren zur schädigung von zellen mit effektorfunktionen von anti-gfra1-antikörpern
WO2007013359A2 (en) * 2005-07-28 2007-02-01 Oncotherapy Science, Inc. Cancer related gene rasgef1a
DE602006021315D1 (de) * 2005-07-29 2011-05-26 Oncotherapy Science Inc Gen und polypeptid in zusammenhang mit brustkrebs
JP2007037421A (ja) * 2005-08-01 2007-02-15 Osaka Univ 大腸癌リンパ節転移の有無を予測するための遺伝子セット
EP1946118A4 (en) * 2005-11-10 2009-01-21 Aurelium Biopharma Inc TISSUE DIAGNOSIS OF BREAST CANCER
WO2007061770A2 (en) * 2005-11-17 2007-05-31 University Of Maryland Method and system for analysis of time-series molecular quantities
EP2295561A3 (en) * 2006-02-03 2011-06-29 Oriental Yeast Co., Ltd. Gene group applicable to cancer prognostication
US8138167B2 (en) 2006-02-10 2012-03-20 Oncotherapy Science, Inc. Methods for treating lung cancers
US20080108065A1 (en) * 2006-04-28 2008-05-08 Indra Poola Systems and diagnostic methods for breast cancer using mmp-1 markers
JP5339291B2 (ja) 2006-08-10 2013-11-13 オンコセラピー・サイエンス株式会社 乳癌に関連する遺伝子およびポリペプチド
US20090311700A1 (en) * 2006-09-27 2009-12-17 Siemens Healthcare Diagnositcs Inc. Methods for Breast Cancer Prognosis
AU2007345912B2 (en) * 2007-02-01 2011-11-24 Oriental Yeast Co., Ltd. Method of detecting mammary cancer cells
EP2118663B1 (en) * 2007-02-15 2014-04-02 Universita' Degli Studi di Torino Regulation of expression of pi3kb protein in tumors
TW200908998A (en) * 2007-06-27 2009-03-01 Oncotherapy Science Inc Compositions and methods of treating cancer
PT2186889E (pt) * 2007-08-20 2015-06-17 Oncotherapy Science Inc Péptido cdca1 e agente farmacêutico que o compreende
US8569244B2 (en) 2007-08-20 2013-10-29 Oncotherapy Science, Inc. FOXM1 peptide and medicinal agent comprising the same
EP2209495A4 (en) * 2007-10-04 2012-05-02 Agency Science Tech & Res TAZ / WWTR1 FOR THE DIAGNOSIS AND TREATMENT OF CANCER
WO2009064933A2 (en) * 2007-11-13 2009-05-22 Ikonisys, Inc. Detection of circulating tumor cells in peripheral blood with an automated scanning fluorescence microscope
US9195796B2 (en) * 2008-01-11 2015-11-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Malignancy-risk signature from histologically normal breast tissue
WO2009116860A1 (en) * 2008-03-17 2009-09-24 Vereniging Het Nederlands Kanker Instituut Markers providing prognosis of metastasis among cancer patients
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
US20100055705A1 (en) * 2008-08-29 2010-03-04 Wilson Gerald M Compositions and methods for diagnosing and treating cancer
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
KR101174369B1 (ko) 2009-05-01 2012-08-16 한국생명공학연구원 유방암 진단용 바이오마커 및 유방암 진단제
WO2010138826A1 (en) * 2009-05-29 2010-12-02 University Of Utah Research Foundation Methods and compositions related to cellular assays
US20110217701A1 (en) * 2010-03-03 2011-09-08 Carter Scott L Prognostic Marker for Endometrial Carcinoma
CN103097548A (zh) * 2010-04-13 2013-05-08 纽约市哥伦比亚大学托管会 基于多癌症侵袭相关机制的生物标记
EP2426216A1 (en) * 2010-09-01 2012-03-07 Institut Gustave Roussy (IGR) Prognostic and/or predictive biomarkers and biological applications thereof
EP3517630B1 (en) 2010-10-06 2022-01-19 Institució Catalana de Recerca i Estudis Avançats Method for the diagnosis, prognosis and treatment of breast cancer metastasis
WO2012056694A1 (ja) 2010-10-26 2012-05-03 国立大学法人山口大学 乳がん発症感受性の判定方法
WO2012066093A1 (en) * 2010-11-19 2012-05-24 Santaris Pharma A/S Compounds for the modulation of pdz-binding kinase (pbk) expression
JP2014502729A (ja) * 2010-12-29 2014-02-03 エクスプレッション、パソロジー、インコーポレイテッド 再発性乳癌のタンパク質バイオマーカー
CN102312002A (zh) * 2011-09-20 2012-01-11 李艳 一种快速检测BRCA1基因mRNA表达量的试剂盒
WO2013061328A2 (en) 2011-10-27 2013-05-02 Yeda Research And Development Co. Ltd. Method of treating cancer
CN104066746B (zh) * 2011-10-28 2017-12-05 肿瘤疗法科学股份有限公司 Topk肽及包含它们的疫苗
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
RU2619739C2 (ru) * 2012-05-30 2017-05-17 Федеральное государственное бюджетное учреждение "Российский научный центр рентгенорадиологии" Министерства здравоохранения российской федерации (ФГБУ "РНЦРР" Минздрава России) Способ диагностики и прогноза при гиперпролиферативных заболеваниях молочной железы
EP2872532A4 (en) 2012-07-10 2016-04-13 Oncotherapy Science Inc CDCA1-EPITOPPEPTIDES FOR TH1 CELLS AND VACCINES THEREWITH
CA2873155C (en) 2012-09-11 2022-07-26 Oncotherapy Science, Inc. Ube2t peptides and vaccines containing the same
EP2938745B1 (en) * 2012-12-26 2020-10-07 Koninklijke Philips N.V. Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
TR201907389T4 (tr) * 2013-10-09 2019-06-21 Fundacio Inst De Recerca Biomedica Irb Barcelona Meme kanserinden kaynaklanan metastazlı kemik kanserinin prognozu ve tedavisine yönelik yöntem.
CA2942721A1 (en) * 2014-03-14 2015-09-17 Czerniecki, Brian J. Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
JP6700512B2 (ja) 2014-08-04 2020-05-27 オンコセラピー・サイエンス株式会社 Ｃｄｃａ１由来ペプチドおよびそれを含むワクチン
US10380834B2 (en) 2015-07-22 2019-08-13 Mark A. Litman Replaceable flexible electronic table top with display function for gaming tables
US10311681B2 (en) 2015-08-19 2019-06-04 Mark A. Litman Electronic table game platform with secondary random event displays
BR112018005581A2 (pt) 2015-10-08 2018-10-16 Oncotherapy Science, Inc. peptídeo derivado de foxm1 e vacina incluindo o mesmo
US11609427B2 (en) 2015-10-16 2023-03-21 Ostendo Technologies, Inc. Dual-mode augmented/virtual reality (AR/VR) near-eye wearable displays
US11106273B2 (en) * 2015-10-30 2021-08-31 Ostendo Technologies, Inc. System and methods for on-body gestural interfaces and projection displays
KR102475128B1 (ko) 2015-11-30 2022-12-07 (주)아모레퍼시픽 Entpd4 억제를 통한 흑색종 예방 또는 치료제, 및 그 스크리닝 방법
KR102541256B1 (ko) 2015-11-30 2023-06-12 (주)아모레퍼시픽 Lipa 억제를 통한 흑색종 예방 또는 치료제, 및 그 스크리닝 방법
US10345594B2 (en) 2015-12-18 2019-07-09 Ostendo Technologies, Inc. Systems and methods for augmented near-eye wearable displays
US10578882B2 (en) 2015-12-28 2020-03-03 Ostendo Technologies, Inc. Non-telecentric emissive micro-pixel array light modulators and methods of fabrication thereof
US10353203B2 (en) 2016-04-05 2019-07-16 Ostendo Technologies, Inc. Augmented/virtual reality near-eye displays with edge imaging lens comprising a plurality of display devices
US10453431B2 (en) 2016-04-28 2019-10-22 Ostendo Technologies, Inc. Integrated near-far light field display systems
US10522106B2 (en) 2016-05-05 2019-12-31 Ostendo Technologies, Inc. Methods and apparatus for active transparency modulation
AU2017271385B2 (en) 2016-05-25 2023-10-05 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-MAF status
BR112018075010A2 (pt) * 2016-06-03 2019-03-12 Kyushu University, National University Corporation proteína de fusão para melhorar o nível de expressão de proteína a partir de rnam alvo
CA3032992C (en) 2016-10-19 2022-04-12 The University Of British Columbia Process for leaching metal sulfides with reagents having thiocarbonyl functional groups
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
JP2020514323A (ja) 2017-02-06 2020-05-21 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物と方法
KR102091747B1 (ko) * 2017-11-15 2020-03-20 주식회사 프로탄바이오 유방암 진단용 바이오마커 및 이의 용도
MX2020005182A (es) 2017-11-22 2020-08-17 Inbiomotion Sl Tratamiento terapeutico del cancer de mama basado en el estado del c-maf.
CN108441559B (zh) * 2018-02-27 2021-01-05 海门善准生物科技有限公司 一种免疫相关基因群作为标志物在制备评估高增殖性乳腺癌远处转移风险的产品中的应用
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN109234384A (zh) * 2018-10-31 2019-01-18 中国医学科学院阜外医院 Hmgcl作为诊断标志物和治疗靶点在致密化不全型心肌病的应用
CN113748215B (zh) * 2018-11-04 2024-07-23 Pfs基因组学公司 用于乳腺癌的预后和预测来自辅助放射疗法的益处的方法和基因组分类器
KR102921276B1 (ko) 2018-11-21 2026-02-03 케이스 웨스턴 리저브 유니버시티 단쇄 데히드로게나아제 활성을 조절하는 조성물 및 방법
CN109811059B (zh) * 2019-03-31 2021-10-19 青岛泱深生物医药有限公司 生物标志物uggt1在宫颈疾病中的应用
WO2022056475A1 (en) * 2020-09-14 2022-03-17 Duke University Compositions and methods for diagnosing and treating a dystonia
AU2021345381A1 (en) 2020-09-18 2023-05-04 Jetti Resources, Llc Extracting base metals using a wetting agent and a thiocarbonyl functional group reagent
CN113025720B (zh) * 2021-04-28 2022-12-27 深圳市人民医院 一种用于检测原发性乳腺弥漫性大b细胞淋巴瘤的标志物及其试剂盒和应用
CN113466447B (zh) * 2021-05-28 2024-03-08 天津市肿瘤医院（天津医科大学肿瘤医院） 诊断胰腺癌预后的肿瘤标志物bzw1及检测试剂盒
CN114931665B (zh) * 2021-12-14 2024-09-27 广州医科大学 六型胶原α2亚基在神经修复产品中的应用
CN114561358B (zh) * 2022-03-09 2023-10-03 广州源井生物科技有限公司 一种提高细胞慢病毒感染率的增强感染培养基及方法
CN114561470B (zh) * 2022-03-19 2024-03-01 新乡医学院 三阴性乳腺癌分子标志物及其应用
CN115616214B (zh) * 2022-09-20 2026-03-03 湖南中医药大学 Sox10抗体的应用、试剂盒
US12366920B2 (en) 2022-09-26 2025-07-22 Pison Technology, Inc. Systems and methods for gesture inference using transformations
US12366923B2 (en) 2022-09-26 2025-07-22 Pison Technology, Inc. Systems and methods for gesture inference using ML model selection
US12340627B2 (en) 2022-09-26 2025-06-24 Pison Technology, Inc. System and methods for gesture inference using computer vision
US12502110B2 (en) 2023-10-24 2025-12-23 Pison Technology, Inc. Systems and methods for determining physiological state based on surface biopotentials
CN118243927A (zh) * 2024-04-29 2024-06-25 东莞市石碣医院 eIF3b作为乳腺癌耐药检测靶点的应用
CN119007982A (zh) * 2024-07-26 2024-11-22 大连医科大学附属第二医院 基于肿瘤浸润边缘e-tls预测非小细胞肺癌预后的方法和设备
CN119955854B (zh) * 2025-01-20 2025-09-09 中国人民解放军军事科学院军事医学研究院 一种侏儒症小鼠模型的构建方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
EP1876241A3 (en) * 1996-01-11 2008-07-30 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US5968747A (en) * 1997-12-12 1999-10-19 Incyte Pharmaceuticals, Inc. Ubiquitin-like conjugating protein
WO2002004514A2 (en) * 2000-07-11 2002-01-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP1425410A2 (en) * 2000-10-03 2004-06-09 Glaxo Group Limited Tumor marker and methods of use
US20030157544A1 (en) * 2000-10-30 2003-08-21 Eos Biotechnology, Inc. Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
US20030104418A1 (en) * 2001-04-27 2003-06-05 Chao Zhang Diagnostic markers for breast cancer
US7189507B2 (en) * 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
CA2500982A1 (en) 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Method for diagnosing testicular seminomas
CN101175862A (zh) 2005-02-10 2008-05-07 肿瘤疗法科学股份有限公司 诊断膀胱癌的方法
JP5339291B2 (ja) 2006-08-10 2013-11-13 オンコセラピー・サイエンス株式会社 乳癌に関連する遺伝子およびポリペプチド
TW200908998A (en) * 2007-06-27 2009-03-01 Oncotherapy Science Inc Compositions and methods of treating cancer

Also Published As

Publication number Publication date
TW200521243A (en) 2005-07-01
US8044193B2 (en) 2011-10-25
JP4620670B2 (ja) 2011-01-26
EP1668354A2 (en) 2006-06-14
ES2365732T3 (es) 2011-10-10
JP4579246B2 (ja) 2010-11-10
CN1898563A (zh) 2007-01-17
WO2005028676A2 (en) 2005-03-31
US20120010090A1 (en) 2012-01-12
EP1668156B9 (en) 2012-02-22
US20070269432A1 (en) 2007-11-22
CN1890381B (zh) 2011-06-22
WO2005029067A2 (en) 2005-03-31
DE602004032556D1 (2) 2011-06-16
CN1898563B (zh) 2011-11-23
WO2005028676A3 (en) 2005-09-15
CN1890381A (zh) 2007-01-03
EP1668156B1 (en) 2011-05-04
EP1668156A2 (en) 2006-06-14
US7531300B2 (en) 2009-05-12
US20090286856A1 (en) 2009-11-19
JP2007506424A (ja) 2007-03-22
TW200512298A (en) 2005-04-01
WO2005029067A3 (en) 2005-08-18
JP2007506426A (ja) 2007-03-22
JP2008092949A (ja) 2008-04-24

Similar Documents

Publication Publication Date Title
ATE508202T1 (de) Verfahren zur diagnose von brustkrebs
ATE419390T1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
WO2006085684A3 (en) Method of diagnosing bladder cancer
WO2005028675A3 (en) Methods for detecting, diagnosing and treating hepatocellular carcinomas (hcc)
WO2007013575A3 (en) Method for diagnosing and treating renal cell carcinoma
DE602005025998D1 (de) Verfahren zur diagnose von nicht-kleinzelligem lungenkrebs
WO2007114896A3 (en) Prognostic and diagnostic method for cancer therapy
DE60237531D1 (de) Verfahren zum trennen von seltenen zellen von fluidproben
WO2008021115A3 (en) Diagnostic tests using gene expression ratios
WO2008021483A3 (en) Prognostic and diagnostic method for disease therapy
JP2015523569A5 (2)
WO2004007770A3 (en) Method for diagnosis of intestinal-type gastric tumors
WO2006036744A3 (en) Methods for a global assay of coagulation and fibrinolysis
CY1117839T1 (el) Γονιδιο τομ34 σχετιζομενο με καρκινο του παχεος εντερου
WO2004021010A3 (en) Method of diagnosing colon and gastric cancers
WO2004058051A3 (en) Androgen-regulated genes and uses for diagnosis, prognosis and treatment of prostate neoplastic conditions
WO2003021229A3 (en) Diagnostic and prognostic tests
TW200643176A (en) ZNFN3A1/breast cancer related gene ZNFN3A1
DE60234958D1 (de) Psoriasin-expression durch brustepithelzellen
ATE494556T1 (de) Verfahren zur diagnose von entzündungserkrankungen und infektionen mittels bestimmung von lasp-1/ lap-1
ATE494390T1 (de) Verfahren und nukleinsäuren zur analyse von störungen der proliferation von kolonzellen
WO2006002240A8 (en) Computer systems and methods for constructing biological classifiers and uses thereof
CN116665784B (zh) 基于cfDNA全基因组测序数据识别染色质开放区域的方法、癌症预测模型及系统
WO2005083118A3 (en) Pin-prc transition genes
JP2012524537A5 (2)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties